AM-Pharma announces positive clinical data from phase 1b study evaluating ilofotase alfa in hypophosphatasia

by Ysios Capital

AM-Pharma B.V. today announced positive clinical results from the Phase 1b study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as potential enzyme replacemen...

Read more

Am-Pharma announces updated clinical development strategy

by Ysios Capital

Advancing ilofotase alfa into a Phase 2 study for lead indication cardiac surgery-associated renal damage

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

New breakthrough in developing more pers...

by Universitat de Barcelona

The results show that adenocarcinoma exhibits much more active and fun...

Photos Stream